Here are top-rated defensive stocks as market rally sputters

Stock Information for Champions Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Champions Oncology Inc.

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.